TABLE 1.

Summary properties of SIV-derived Mamu-A*01 peptides

SIV Gene	Peptide name	Amino Acid Sequence	Reference	MFI	% IFN-γ CD8+ T cells
Gag	LA9	LAPVPIPFA	(Allen et al., 2001)	23.4	9.52
Gag	CM9	CTPYDINQM	(Allen et al., 1998)	34.4	67.25
Gag	LW9	LSPRTLNAW	(Allen et al., 2001)	1.72	7.81
Pol	LV10	LGPHYTPKIV	(Allen et al., 2001)	1.58	4.02
Pol	SV9	STPPLVRLV	(Egan et al., 1999)	45.8	10.1
Pol	GM10	GSPAIFQYTM	(Allen et al., 2001)	9.06	2.51
Pol	MI8	MTPAERLI	(Allen et al., 2001)	11.2	4.65

Seven previously defined Mamu-A*01 restricted SIV Gag and Pol epitopes were tested for stabilization of cell surface expression of Mamu-A*01/K^b in RMA-S cells, and induction of intracellular IFN-γ production in CD8⁺ T cells after IVS of rVV-SIVGag-Pol immunized Mamu-A*01/Kb Tg mice (N=2) for each peptide. Background binding to a control peptide was subtracted for RMA-S assays, and the percentage of IFN-γ⁺ CD8⁺ T cells from a mock-stimulated culture was subtracted from all ICC assay results. The mean fluorescence intensity (MFI) and percentage of intracellular IFN-γ positive of CD8⁺ T cells were determined by flow cytometry using a FACS-Canto^™ (BDIS, San Jose, CA). Results shown are an average of N=2 mice with <25% standard error from the mean.